OTCMKTS:CPHRF Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis $9.30 -0.42 (-4.32%) As of 10/30/2026 03:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.30▼$9.6350-Day Range$9.30▼$10.6552-Week Range$8.92▼$15.00Volume3,606 shsAverage Volume4,948 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cipher Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused primarily on developing, acquiring, and commercializing medicines for dermatology and other areas with unmet medical needs. The company’s business model emphasizes licensing and advancing differentiated prescription products rather than maintaining a broad, traditional drug-discovery operation. Cipher’s dermatology portfolio has included Epuris, an oral isotretinoin product used to treat severe acne, as well as products for conditions such as actinic keratosis and excessive facial hair. The company has also pursued opportunities to expand its portfolio through product acquisitions, licensing agreements, and regulatory development in selected markets. Cipher serves healthcare providers and patients primarily in Canada and the United States, with its commercial reach depending on the specific product and applicable regulatory approvals. The company is headquartered in Canada and has historically operated as a commercial-stage pharmaceutical business focused on specialized prescription therapies.AI Generated. May Contain Errors. Read More Receive CPHRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPHRF Stock News HeadlinesCipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration AwardSeptember 1, 2026 | finance.yahoo.comCipher Pharmaceuticals Balances U.S. Strain With Epuris StrengthAugust 25, 2026 | theglobeandmail.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 31 at 1:00 AM | Digest Publishing (Ad)Cipher Pharmaceuticals Inc (CPHRF) (Q2 2026) Earnings Call Highlights: Epuris Growth and ...August 12, 2026 | finance.yahoo.comCipher Pharmaceuticals Inc CPHRFAugust 4, 2026 | morningstar.comMCipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®July 6, 2026 | finance.yahoo.comCaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)April 7, 2026 | businesswire.comCipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 13, 2026 | finance.yahoo.comSee More Headlines CPHRF Stock Analysis - Frequently Asked Questions How have CPHRF shares performed this year? Cipher Pharmaceuticals' stock was trading at $10.98 on January 1st, 2026. Since then, CPHRF stock has decreased by 15.3% and is now trading at $9.30. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.06. The business earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPH), Alibaba Group (BABA), Aurora Cannabis (ACB), AutoCanada (ACQ), Alliance Growers (ACGWF), ACADIA Pharmaceuticals (ACAD) and Autodesk (ADSK). Company Calendar Last Earnings5/05/2016Today10/31/2026Next Earnings (Estimated)11/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CIKN/A Webwww.cipherpharma.com Phone(905) 602-5840FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:CPHRF) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
